secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-09-29T20:45:42+00:00
Accession:  0001193125-26-407696
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Phathom starts patient screening in Phase 3 pHalcon-NERD-302 testing as-needed VOQUEZNA for Non-Erosive GERD
--------------------------------------------------------------------------------

- Phathom announced initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study of as-needed VOQUEZNA (vonoprazan) 10 mg in adults with Non-Erosive GERD.
- Topline results are expected in the first quarter of 2028; if successful, the study would support a regulatory submission for a VOQUEZNA label expansion.
- The trial is expected to enroll approximately 500 adults with heartburn at least four days per week at roughly 80 U.S. sites.
- After a four-week open-label run-in, patients are randomized 1:1 to VOQUEZNA 10 mg or placebo as-needed for 24 weeks, with the primary endpoint assessed at Week 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/0001193125-26-407696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-407696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer